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All governments have approved the Global Monitoring Framework on Non-communicable 
Diseases (NCDs), which includes a commitment to reduce premature NCD (including 
cancer-related) deaths by 25% by 2025. The global monitoring framework requires WHO 
member states to collect cancer incidence, by type of cancer per 100,000 population – one of 
25 indicators to monitor progress toward the 25 by 25 targets [1]. Population-based cancer 
registries are units that collect and report high quality data on cancer incidence. The data 
generated by population-based cancer registries are essential for informing health programs, 
policies and strategies regarding cancer screening and treatment, and for evaluating the 
impact of national programs for cancer prevention, screening, and treatment [2,3]. However, 
there are large differences in the existence, coverage and quality of cancer registration across 
☆The findings and conclusion of this presentation do not necessarily represent the official position of the U.S. Centers for Disease 
Control and Prevention.
*Corresponding author at: Centers for Disease Control and Prevention, DCPC, 4770 Buford Highway, NE, Mailstop K-76, Atlanta, 
GA, 30341-3717, United States. MSaraiya@cdc.gov (M. Saraiya). 
Author contributions
Mona Saraiya: Lead author; editorial conception and design, editorial draft, revised editorial for intellectual and scientific content; 
reviewed and approved final version to be published.
Florence Tangka: Co-author; editorial conception and design, editorial draft, revised editorial for intellectual and scienti c content; 
reviewed and approved final version to be published.
Samira Asma: Co-author; editorial draft, revised editorial for intellectual and scientific content; reviewed and approved final version to 
be published.






Cancer Epidemiol. Author manuscript; available in PMC 2017 December 01.
Published in final edited form as:













the world. The percentage of the population covered by cancer registries that meet the 
quality standards for inclusion in global statistics (Cancer Incidence in Five Continents – 
CI5) ranges from near-complete coverage in North America to less than 10% coverage in 
Asia, Central and South America, and Africa [4] (See Fig. 1).
Given these stark statistics, there is an urgent need to initiate sustainable cancer registration 
models in many countries and to improve existing registration infrastructure to ensure that 
high quality population-based cancer incidence data are available. The global community 
requires information on the resources required to initiate, improve and expand cancer 
registration in order to fund registries adequately. In this monograph, cost and resource data 
are presented from cancer registries in five countries: India, Kenya, Uganda, Barbados and 
Colombia. A standardised activity–based cost approach [5–7], validated in the United States 
setting, was pilot-tested and adopted for use internationally. The results from 11 registries 
included in this monograph show wide variation, with the cost of registration for a single 
cancer case varying from about $4 to $113 for registries in low and middle income 
countries. The global team of collaborators identified several factors that might explain the 
differences in cost including size of area served, quality of the data available at provider 
sites, number of reporting facilities and cost of living variation. A key finding is that in all 
settings the cost of cancer registration at the population level in the coverage area is 
extremely small, a few cents per individual served across the population.
Cancer registration requires adequate resources to generate high-quality statistics but the 
benefit gained through data-driven policies can be substantial; prevention, early detection of 
cancers and appropriate treatment can significantly reduce the burden from cancer. In the 
United States, it cost on average $65 to register a cancer case [8] and approximately $75 
million is spent on cancer registration activities annually. In contrast, over $157 billion was 
spent on cancer treatment in 2010 [9] and the cost of lost productivity due to premature 
cancer mortality was approximately $130 billion [10]. Furthermore, global and national 
statistics often do not capture the substantial financial burden experienced by many cancer 
patients and their families, particularly in low and middle income countries. In India, for 
example, cancer patients often pay large out-of-pocket expenses for treatment, which can 
severely impact, or even exhaust, household savings [11,12].
The series of manuscripts published in this monograph offer several lessons for planning and 
supporting cancer registration. First, the lack of continuous sustained support for registry 
infrastructure can lead to disruptions in data collection and potential inefficient use of 
resources. The contribution of a host institution (be it an academic entity or hospitals or 
other type) improves sustainability but support from the national government or other 
entities may be key for most cancer registration to produce high-quality data. Second, 
although registries incur substantial fixed cost, higher volume registries will have lower cost 
per case, generating large economies of scale. Innovative models and approaches to share 
resources can result in lower registration costs. These could include the development of 
integrated NCD registries, especially for island nations with small populations in the 
Caribbean and Pacific, including the US Virgin Islands and the US-affiliated Pacific Islands. 
Third, the data presented in this monograph can serve as baseline information to identify 
efficiencies in data collection methods, which is consistently reported as a high cost activity 
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across the registries. Electronic data collection approaches could increase efficiency and 
reduce cost of cancer registration. Fourth, cancers such as nonmelanoma skin cancers, 
represent a significant proportion of cases and their monitoring may not be an efficient use 
of resources for cancer registries with limited funding. In the United States, a decision was 
made to exclude these cancers based on the number of cases that would need to be found 
and data collected. Lastly, monitoring and prioritizing cancers that have evidence-based 
interventions may be important for cancer registries. For example, many cancer registries in 
the Caribbean collect information on high grade pre-invasive cervical cancer (cervical 
intraepithelial neoplasia III or CIN III)—these may be important for monitoring impact of 
screening and vaccination. In the United States, select cancer registries have opted to begin 
looking at CINIII in cancer registries after several decades of not collecting these data [13].
CDC is partnering with a large number of countries, national and international partners, 
including the International Agency for Research on Cancer, to improve cancer registration 
and with the Bloomberg Data for Health Initiative to improve cause of death globally [14], 
both with a specific focus on low and middle income countries. The series of studies 
presented in this monograph is an important step forward in generating the required 
evidence-base and CDC remains committed to working with a broad coalition of 
stakeholders to further advance sustainable models for NCDs, in particularly cancer 
registration in the future.
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Global status of Population-Based Cancer Registration as of mid-2013.
Notes: PBCR stands for Population-Based Cancer Registries. “High-quality PBCR” implies 
publication in Cancer Incidence in Five Continents Volume X. Source: Courtesy of Freddie 
Bray, IARC.
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